Journal of Internal Medicine Concepts & Practice >

2023 , Vol. 18 >Issue 05: 372 - 376

DOI: https://doi.org/10.16138/j.1673-6087.2023.05.014

Review article

Research progress of sputum analysis in the diagnosis, treatment and assessment of chronic obstructive pulmonary disease

Expand

Received date: 2023-03-09

  Online published: 2024-01-25

Fold

Cite this article

WANG Cui, JIANG Guogang, CUI Xiaoli . Research progress of sputum analysis in the diagnosis, treatment and assessment of chronic obstructive pulmonary disease[J]. Journal of Internal Medicine Concepts & Practice, 2023 , 18(05) : 372 -376 . DOI: 10.16138/j.1673-6087.2023.05.014

References

[1] Der Mesropian PJ, Shaikh G, Beers KH, et al. Effect of intensive blood pressure on the progression of non-diabetic chronic kidney disease at varying degrees of proteinuria[J]. J Investig Med, 2021, 69(5): 1035-1043.
[2] Afsar B, Afsar RE, Copur S, et al. The effect of energy restriction on development and progression of chronic kidney disease: review of the current evidence[J]. Br J Nutr, 2021, 125(11): 1201-1214.
[3] Wang C, Xu J, Yang L, et al. China pulmonary health study group[J]. Lancet, 2018, 391(101311):1706-1717.
[4] O’Donnell DE, Parker CM. COPD exacerbations 3: pathophysiology[J]. Thorax, 2006, 61(4): 354-361.
[5] Celli BR, Barnes PJ. Exacerbations of chronic obstructive pulmonary disease[J]. Eur Respir J, 2007, 29(6): 1224-1238.
[6] 刘奇, 陆欢, 单梦田, 等. 头罩无创通气在慢性阻塞性肺疾病急性加重合并呼吸衰竭患者中的应用[J]. 中华危重病急救医学, 2020, 32(1): 14-19.
[7] Miravitlles M, Alcázar B, Soler-Catalu?a XX. The concept of control in chronic obstructive pulmonary disease: development of the criteria and validation for use in cli-nical practice[J]. Russian Pulmonology, 2020, 30(2): 135-141.
[8] Dicker AJ, Huang JTJ, Lonergan M, et al. The sputum microbiome, airway inflammation, and mortality in chro-nic obstructive pulmonary disease[J]. J Allergy Clin Immunol, 2021, 147(1): 158-167.
[9] Armitage MN, Spittle DA, Turner AM. A systematic review and meta-analysis of the prevalence and impact of pulmonary bacterial colonisation in stable state chronic obstructive pulmonary disease(COPD)[J]. Biomedicines, 2021, 10(1): 81.
[10] 翟红瑞, 罗松平, 林磊, 等. 无创-有创机械通气序贯性治疗慢性阻塞性肺疾病急性加重中切换时机的临床研究[J]. 中华危重病急救医学, 2020, 32(2): 161-165.
[11] Liu Y, Zeng S, Li Y, et al. The effect of acupoint application of traditional Chinese medicine for the treatment of chronic obstructive pulmonary disease: a protocol for systematic review and meta-analysis[J]. Medicine, 2020, 99(43): e22730.
[12] Pooni RS, Corbett R. serum urate reduction and its effect on the progression of chronic kidney disease[J]. Clin Med (Lond), 2020, 20(5): 448.
[13] Karnaushkina MA, Fedosenko SV, Danilov RS, et al. Eosinophilic cationic protein as a non-invasive marker of the nature of inflammatory response in patients with chronic obstructive pulmonary disease[J]. Bulletin of Siberian Medicine, 2020, 19(1): 59-66.
[14] Zhang J, He X, Hu J, et al. Failure of early extubation among cases of coronavirus disease-19 respiratory failure: case report and clinical experience[J]. Medicine, 2020, 99(27): e20843.
[15] Wu JJ, Zhang YX, Xu HR, et al. Effect of acupoint application on T lymphocyte subsets in patients with chronic obstructive pulmonary disease[J]. Medicine, 2020, 99(16): e19537.
[16] Taraseviciene-Stewart L, Douglas IS, Nana-Sinkam PS, et al. Is alveolar destruction and emphysema in chronic obstructive pulmonary disease an immune disease?[J]. Proc Am Thorac Soc, 2006, 3(8): 687-690.
[17] Pragman AA, Kim HB, Reilly CS, et al. The lung microbiome in moderate and severe chronic obstructive pulmonary disease[J]. PLoS One, 2012, 7(10): e47305.
[18] Dicker AJ, Huang JTJ, Lonergan M, et al. The sputum microbiome, airway inflammation, and mortality in chronic obstructive pulmonary disease[J]. J Allergy Clin Immunol, 2021, 147(1): 158-167.
[19] Bouquet J, Tabor DE, Silver JS, et al. Microbial burden and viral exacerbations in a longitudinal multicenter COPD cohort[J]. RRespir Res, 2020 Mar 30; 21(1): 77.
[20] Wang Z, Locantore N, Haldar K, et al. Inflammatory endotype-associated airway microbiome in chronic obstructive pulmonary disease clinical stability and exacerbations[J]. Am J Respir Crit Care Med, 2021, 203(12): 1488-1502.
[21] Francis NA, Gillespie D, White P, et al. C-reactive protein point-of-care testing for safely reducing antibiotics for acute exacerbations of chronic obstructive pulmonary disease: the PACE RCT[J]. Health Technol Assess, 2020, 24(15): 1-108.
[22] Han MK, Huang YJ, Lipuma JJ, et al. Significance of the microbiome in obstructive lung disease[J]. Thorax, 2012, 67(5): 456-63.
[23] Einarsson GG, Comer DM, McIlreavey L, et al. Community dynamics and the lower airway microbiota in stable chronic obstructive pulmonary disease, smokers and healthy non-smokers[J]. Thorax, 2016, 71(9): 795-803.
[24] Shukla SD, Budden KF, Neal R, et al. Microbiome effects on immunity, health and disease in the lung[J]. Clin Transl Immunology, 2017, 6(3): e133.
[25] Aguirre E, Galiana A, Mira A, et al. Analysis of microbiota in stable patients with chronic obstructive pulmonary disease[J]. APMIS, 2015, 123(5): 427-432.
[26] Huang YJ, Sethi S, Murphy T, et al. Airway microbiome dynamics in exacerbations of chronic obstructive pulmonary disease[J]. J Clin Microbiol, 2014, 52(8): 2813-2823.
[27] Erb-Downward JR, Thompson DL, Han MK, et al. Analysis of the lung microbiome in the “healthy” smoker and in COPD[J]. PLoS One, 2011, 6(2): e16384.
[28] Kurai D, Saraya T, Ishii H, et al. Virus-induced exacerbations in asthma and COPD[J]. Front Microbiol, 2013, 4:293.
[29] Pragman AA, Kim HB, Reilly CS, et al. The lung microbiome in moderate and severe chronic obstructive pulmonary disease[J]. PLoS One, 2012, 7(10): e47305.
[30] Leung JM, Tiew PY, Mac Aogáin M, et al. The role of acute and chronic respiratory colonization and infections in the pathogenesis of COPD[J]. Respirology, 2017, 22(4):634-650.
[31] Sethi S. Chronic obstructive pulmonary disease and infection. Disruption of the microbiome?[J]. Ann Am Thorac Soc, 2014, 11 Suppl 1: S43-S47.
[32] Ergan B, Topeli A. Antibiotic decision in severe chronic obstructive pulmonary disease exacerbations[J]. Respiration, 2017, 94(1): 75.
[33] Stockley RA. Biomarkers in chronic obstructive pulmonary disease: confusing or useful?[J]. Int J Chron Obstruct Pulmon Dis, 2014, 9: 163-77.
[34] Goeminne PC, Vanfleteren LEGW. Bronchiectasis economics: spend money to save money[J]. Respiration, 2018, 96(5): 399-402.
[35] Halfawy AA, Abdelhafiz H, Kamal E, et al. Characteristic features and percentage of asthma chronic obstructive pulmonary disease overlap among patients with obstructive airway diseases[J]. Egypt J Chest Dis Tuberc, 2020, 67(4): 356-360.
[36] Meng W, Cao X, Sun W, et al. A functional polymorphism at the miR-491-5p binding site in the 3’-untranslated region of the MMP-9 gene increases the risk of developing ventilator-associated pneumonia[J]. Int J Mol Med, 2021, 48(6): 217.
[37] Venegas C, Zhao N, Ho T, et al. Sputum inflammometry to manage chronic obstructive pulmonary disease exacerbations: beyond guidelines[J]. Tuberc Respir Dis (Seoul), 2020, 83(3):175-184.
[38] Zhang F, Zhong Y, Qin Z, et al. Effect of muscle training on dyspnea in patients with chronic obstructive pulmonary disease[J]. Medicine (Baltimore), 2021, 100(9):e24930.
[39] Huang J, Bian Y, Zhao Y, et al. The impact of depression and anxiety on chronic obstructive pulmonary disease acute exacerbations[J]. J Affect Disord, 2021, 281:147-152.
[40] Kumar PA, Sreekanth AS. A study on overview of asthma-chronic obstructive pulmonary disease overlaps among patients with obstructive airway diseases[J]. IJIRM, 2021, 6(2): 117-120.
[41] Park MH, Kim MJ, Kim AJ, et al. Helmet-based noninvasive ventilation for acute exacerbation of chronic obstructive pulmonary disease[J]. World J Clin Cases, 2020, 8(10): 1939-1943.
[42] King AH, Kwan S, Kim A, et al. Effect of the neutrophil/lymphocyte ratio on outcome after carotid endarterectomy and carotid artery disease progression[J]. J Am Coll Surg, 2020, 231(4): S343.
[43] Wilkinson TM, Patel IS, Wilks M, et al. Airway bacterial load and FEV1 decline in patients with chronic obstructive pulmonary disease[J]. Am J Respir Crit Care Med, 2003, 167(8): 1090-1095.
[44] Sethi S, Evans N, Grant BJ, et al. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease[J]. N Engl J Med, 2002, 347(7): 465-471.
[45] Agustí A, Vestbo J. Current controversies and future perspectives in chronic obstructive pulmonary disease[J]. Am J Respir Crit Care Med, 2011, 184(5): 507-513.
[46] Garcha DS, Thurston SJ, Patel AR, et al. Changes in prevalence and load of airway bacteria using quantitative PCR in stable and exacerbated COPD[J]. Thorax, 2012, 67(12): 1075-1080.
[47] Huang YJ, Sethi S, Murphy T, et al. Airway microbiome dynamics in exacerbations of chronic obstructive pulmonary disease[J]. J Clin Microbiol, 2014, 52(8): 2813-2823.
[48] Pragman AA, Knutson KA, Gould TJ, et al. Chronic obstructive pulmonary disease upper airway microbiota alpha diversity is associated with exacerbation phenotype: a case-control observational study[J]. Respir Res, 2019, 20(1): 114.
[49] Wisor JP, Holmedahl NH, Saxvig IW, et al. Effect of dietary nitrate supplementation on sleep in chronic obstructive pulmonary disease patients[J]. Nat Sci Sleep, 2021, 13: 435-446.
[50] Muggeo A, Perotin JM, Brisebarre A, et al. Extended bacteria culture-based clustering identifies a phenotype associating increased cough and enterobacterales in stable chronic obstructive pulmonary disease[J]. Front Microbiol, 2021, 12: 781797.
[51] Onuska KM. The dual role of microglia in the progression of Alzheimer’s disease[J]. J Neurosci, 2020, 40(8):1608-1610.
[52] Ra SW, Kwon YS, Yoon SH, et al. Sputum bacteriology and clinical response to antibiotics in moderate exacerbation of chronic obstructive pulmonary disease[J]. Clin Respir J, 2018, 12(4): 1424-1432.
[53] Messous S, Grissa MH, Beltaief K, et al. Bacteriology of acute exacerbations of chronic obstructive pulmonary disease in Tunisia[J]. Rev Mal Respir, 2018, 35(1): 36-47.
[54] Szylińska A, Kotfis K, Listewnik M, et al. The burden of chronic obstructive pulmonary disease in open heart surgery-a retrospective cohort analysis of postoperative complications[J]. Medicine (Baltimore), 2020, 99(13):e19675.
[55] Arafa MA. Sputum bacteriology in patients with acute exacerbation of chronic obstructive pulmonary disease[J]. Egypt J Hos Med, 2021, 84(1): 2510-2515.
[56] Wang Z, Locantore N, Haldar K, et al. Inflammatory endotype-associated airway microbiome in chronic obstructive pulmonary disease clinical stability and exacerbations[J]. Am J Respir Crit Care Med, 2021, 203(12): 1488-1502.
[57] Kim EK, Singh D, Park JH, et al. Impact of body mass index change on the prognosis of chronic obstructive pulmonary disease[J]. Respiration, 2020, 99(11): 943-953.
[58] Singh D, Lea S, Mathioudakis AG. Inhaled phosphodiesterase inhibitors for the treatment of chronic obstructive pulmonary disease[J]. Drugs, 2021, 81(16): 1821-1830.
[59] Leitao Filho FS, Takiguchi H, Akata K, et al. Effects of inhaled corticosteroid/long-acting β2-agonist combination on the airway microbiome of patients with chronic obstructive pulmonary disease[J]. Am J Respir Crit Care Med, 2021, 204(10): 1143-1152.
[60] Wang Z, Maschera B, Lea S, et al. Airway host-microbiome interactions in chronic obstructive pulmonary disease[J]. Respir Res, 2019, 20(1): 113.
[61] Meteran H, Thomsen SF, Miller MR, et al. Impact of the spirometric definition on comorbidities in chronic obstructive pulmonary disease[J]. Respir Med, 2021, 184:106399.
Options
Outlines

/

〈 〉